Preventing Muscle Loss on GLP-1 Medications: What Every Woman Needs to Know

GLP-1 medications produce impressive weight loss. What the headlines rarely mention is that a meaningful portion of that weight is muscle, not fat. In the STEP 1 trial, approximately 39% of total weight lost was lean mass. That figure should give every woman starting these medications pause.

Muscle is not just aesthetic. It is the engine of your metabolism, the foundation of your functional strength, and a key determinant of long-term weight maintenance. Losing it while trying to improve your health is a genuinely significant problem, and it's a problem that gets worse the older you are.

The Scale of the Problem

In the STEP 1 semaglutide trial, participants lost an average of 14.9% of body weight over 68 weeks. Dual-energy X-ray absorptiometry (DEXA) scans showed that approximately 39% of that total weight loss was lean mass, which includes muscle, bone, and connective tissue. Fat mass accounted for the remaining 61%.

For a woman who starts at 100kg and loses 15kg, this means roughly 5.85kg of lean tissue lost and 9.15kg of fat. That sounds acceptable on paper. In practice, 5.85kg of muscle loss represents a meaningful reduction in metabolic capacity, physical strength, and insulin sensitivity.

More recent tirzepatide data from the SURMOUNT trials shows a similar pattern, though the lean mass loss percentage is marginally lower, possibly because tirzepatide's dual GLP-1/GIP mechanism has additional effects on fat partitioning.

Why Women Are More Vulnerable

Baseline Muscle Mass

Women have less muscle mass than men as a proportion of body weight. This means the absolute amount of muscle available to lose is smaller, and any percentage loss has greater functional impact.

Post-Menopausal Muscle Loss

After menopause, oestrogen levels fall. Oestrogen has a protective effect on muscle tissue, partly by modulating satellite cell activity (the muscle stem cells responsible for repair and growth). After menopause, muscle synthesis rates decline and muscle breakdown rates increase, a state called anabolic resistance. This makes it harder to build new muscle and easier to lose existing muscle during caloric restriction.

Women in their 40s, 50s, and 60s, who represent a large proportion of GLP-1 users, are therefore at disproportionate risk of accelerated muscle loss during GLP-1 treatment. For more detail on GLP-1 use around menopause specifically, see the GLP-1 and menopause guide.

Anabolic Resistance and Protein Utilisation

Older women and post-menopausal women require more dietary protein to achieve the same muscle protein synthesis response as younger adults. Where a 25-year-old might maintain muscle adequately on 1.4g of protein per kg of body weight, a 55-year-old woman on GLP-1 medication during caloric restriction may need 1.8-2.0g per kg to achieve comparable protection.

The Evidence: Resistance Training Dramatically Changes the Outcome

The most significant intervention for preserving muscle on GLP-1 therapy is resistance training. A 2024 meta-analysis of exercise interventions during GLP-1 treatment is particularly clear on this.

A 68% reduction in lean mass loss is a substantial effect. It means that the difference between doing resistance training and not doing it is the difference between losing 2kg of muscle and losing 6kg of muscle over a typical treatment course. This is not a marginal benefit. It's a transformative one.

The mechanism is straightforward: resistance training signals muscle fibres to adapt and grow, even in a caloric deficit. Combined with adequate protein intake, this anabolic signal is strong enough to partially or completely offset the catabolic effect of the deficit itself.

The Resistance Training Protocol

Minimum Effective Dose

Two to three sessions per week of compound resistance exercises is the evidence-backed minimum for muscle preservation. You do not need to spend hours in a gym.

A session of 30-45 minutes covering the major muscle groups is sufficient. The key variables are:

• Progressive overload: Each session, aim to lift slightly more weight or complete slightly more reps than the previous. Muscles adapt only when challenged.
• Compound movements: Focus on exercises that work multiple muscle groups simultaneously: squats, deadlifts, rows, pressing movements, lunges. These produce the strongest anabolic signal.
• Sets and reps: 3-4 sets of 8-12 reps per exercise, working to within 2-3 reps of failure, is the established range for hypertrophy and muscle preservation.

Getting Started Without a Gym

If gym access is limited, bodyweight resistance training and resistance bands produce meaningful muscle-preserving effects, particularly for beginners. The body doesn't distinguish between a barbell and gravity. What matters is progressive challenge and compound movement patterns.

Exercises you can do at home:

• Squats and split squats (progress to Bulgarian split squats)
• Press-ups (progress to deficit press-ups)
• Hip thrusts with a heavy bag or loaded backpack
• Rows with a resistance band anchored to a door
• Step-ups with bodyweight, then adding load

For a structured exercise plan that incorporates resistance training into a GLP-1 programme, the Wegovy exercise plan provides a week-by-week framework.

The Protein Protocol

Resistance training preserves muscle only when protein intake is sufficient to support repair and synthesis. Without adequate protein, the anabolic signal from training cannot be fully utilised.

Target: 1.6-2.0g of protein per kilogram of body weight daily.

For a post-menopausal woman, 2.0g per kg is a more conservative and protective target. For a 75kg woman, that's 150g of protein daily, distributed across meals.

Distribution matters. Consuming protein across 3-4 meals of 30-40g each is more effective for muscle protein synthesis than consuming the same total amount in 1-2 large portions.

The guide to diet on GLP-1 medications covers practical protein sources and daily meal planning in detail.

Creatine: The Evidence for Women Over 40

Creatine monohydrate is one of the most extensively studied supplements in sports nutrition, and its benefits extend well beyond athletes. For women over 40 on GLP-1 medications, it has specific relevance.

Creatine supports phosphocreatine regeneration in muscle, allowing for greater training volume and intensity. Over time, this translates to better muscle preservation and strength outcomes. For post-menopausal women, there's additional evidence that creatine supplementation may support bone density, a secondary concern for women losing weight rapidly.

Dose: 3-5g of creatine monohydrate daily, taken at any time of day. No loading phase required. Effects accumulate over 4-6 weeks of consistent use.

Common concerns:

• Water retention: Creatine causes mild intracellular water retention (in the muscle cells), which may show as 1-2kg of additional scale weight. This is not fat gain and does not reflect on the scale measurement that matters.
• Safety: Creatine has a strong safety record across decades of research. No evidence of kidney harm in healthy adults at standard doses.

Testing: Knowing What You're Starting With

If you want to track lean mass accurately over your GLP-1 treatment course, a DEXA scan at baseline gives you the numbers to compare against. Some GP practices offer this; most require a private referral or self-funded scan.

Alternatively, functional tests provide a practical proxy: track how much weight you can lift in key exercises over time. If your squat or row weight is improving over months, you are preserving or building muscle regardless of what the scale shows.

Blood markers also matter. GLP-1 therapy's metabolic effects go well beyond the scale. For a complete guide to what to test before and during treatment, see the GLP-1 blood tests guide.

What About Muscle Loss Side Effects?

Some women on GLP-1 medications notice muscle weakness, reduced exercise tolerance, or what feels like general physical deconditioning in the first few months. This is usually a combination of:

• Caloric deficit effects: Less energy available for physical performance
• Reduced food volume: Less glycogen stored from lower carbohydrate intake
• Deconditioning: Less movement overall if nausea or fatigue has reduced activity levels

These effects improve as the body adapts, as side effects settle, and as resistance training stimulates adaptation. They are not signs of serious pathology in most cases.

For a full guide to managing physical side effects, see the women's side effects guide for Wegovy.

The Priority Stack

If you're starting GLP-1 therapy, or already on it and realising you've not addressed muscle loss, here is the priority order:

1. Start resistance training this week. Two sessions is enough to begin.
2. Hit 1.6-2.0g of protein per kg of body weight daily.
3. Add creatine monohydrate (3-5g daily) if you're post-menopausal or over 40.
4. Track muscle preservation with functional tests (lift weights) or DEXA.
5. Review body composition at 6 months, not just scale weight.

The medication will take the weight off. The protocol above determines what you're left with when it does.